Key result
Intravenous stem cell therapy administered post-angioplasty significantly reduced the 12-month restenosis rate to 12% compared to 27% with standard care.
Why the study?
Post-procedural complications after angioplasty, particularly restenosis, remain a concern, and the clinical understanding of regenerative stem cell therapy following angioplasty is still emerging.
Does intravenous autologous stem cell therapy reduce the rate of restenosis at 12 months in CAD patients undergoing angioplasty?
RCT (n=500)
Double-blind
Computer-generated random number sequence
Yes
Does intravenous autologous stem cell therapy reduce the rate of restenosis at 12 months in CAD patients undergoing angioplasty?
Absolute Event Rate: 12% vs 27%
p-value: p=<0.001
Intravenous autologous stem cell therapy administered 24 hours post-angioplasty significantly reduces 12-month restenosis rates and intimal hyperplasia while improving quality of life in CAD patients.
Supports adjunctive stem cell therapy post-angioplasty in CAD; extends randomized evidence for cell-based restenosis prevention.
Introduction: Cardiovascular diseases (CVDs) continue to be a primary global health challenge, responsible for significant morbidity and mortality. Despite the advancements in therapeutic modalities, challenges persist. Angioplasty stands out as a key intervention for coronary artery disease (CAD), but post-procedural complications, particularly restenosis, remain a concern. Stem cells, given their regenerative properties, have garnered attention as a potential therapeutic avenue following angioplasty, but clinical understanding is still emerging. Objective: This study aimed to investigate the therapeutic potential of stem cell administration following angioplasty in reducing restenosis rates and improving vascular repair. Methods: A randomized controlled trial was conducted with 500 CAD patients (aged 45-75) undergoing angioplasty. Participants were randomly allocated to control (standard post-angioplasty care) and experimental groups (standard care + stem cell therapy). Primary outcome was the rate of restenosis at 12 months, with secondary outcomes like intimal hyperplasia and quality of life assessed using EQ-5D. Results: At 12-month follow-up, the restenosis rate was significantly lower in the experimental group (12%) than in the control group (27%) [p<0.001]. Additionally, the experimental group demonstrated a 40% reduction in intimal hyperplasia and reported higher quality of life scores compared to controls. Discussion: Our results signify the potential benefits of stem cell therapy post-angioplasty. The marked reduction in restenosis aligns with prior pre-clinical evidence highlighting stem cells' reparative capacities. Limitations include the study's 12-month duration and the specific age bracket of participants. Conclusions: Stem cell therapy after angioplasty shows promise in reducing restenosis and improving patient outcomes. More long-term studies are essential to solidify these findings and guide clinical applications.
No takes yet. Share an insight, caveat, or question.
Sabih Ahmed (2023) conducted an RCT in Coronary artery disease (n=500). Intravenous stem cell therapy vs. Standard post-angioplasty care was evaluated on Rate of restenosis at 12 months (p=<0.001). Intravenous stem cell therapy administered post-angioplasty significantly reduced the 12-month restenosis rate to 12% compared to 27% with standard care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: